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Abstract
Background: Somatic copy number alterations (CNAs) contribute to the clinically targetable aberrations in the
tumor genome. For both routine diagnostics and biomarkers research, CNA analysis in a single assay together with
somatic mutations is highly desirable.
Results: Ioncopy is a validated method and easy-to-use software for CNA calling from targeted NGS data. Copy
number and significance of CNA are estimated for each gene in each sample. Copy number gains and losses are
called after multiple testing corrections controlling FWER or FDR.
Conclusions: Ioncopy facilitates calling of CNAs in a cohort of tumors tissues with or without using normal
(germline) DNA controls.
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Background
In addition to conventional somatic mutations such as
point mutations and small indels, clinically relevant
genetic alterations in tumors include large-scale somatic
aberrations such as translocations and copy number
alterations (CNAs). As classical example of an actionable
CNA, testing for HER2 amplifications revolutionized
breast cancer care, since the FDA approved Herceptin
for the treatment of metastatic and later for early breast
cancer [1]. Both the numbers of patients and genes com-
monly tested for amplifications in routine diagnostics
keep continuously growing. For example, amplified
HER2, MET and FGFR1 are potential drug targets in
lung and other cancers [2–4]. MDM2 is used in diagnos-
tics of liposarcoma [5] and has recently been described
to be associated with hyperprogression of metastatic
cancer after immune therapy [6].
Gene amplifications are usually tested using in situ
hybridization (ISH) based assays. On the other hand, tar-
geted NGS, e.g. using the IonTorrent S5 or the Illumina
MiSeq platform, is the today’s mainstay for routine testing
of mutations. Therefore, integrating mutation analysis and
CNA detection in a single assay would be highly desirable
for both routine diagnostics and biomarker research.
Calling of CNAs from targeted sequencing data has
shown to be feasible by several authors after publication
of the first larger study [7]. Sensitivities obtained for
HER2 amplification calling in breast cancer range
between 89% and 93% at specificities between 98% and
100% [8–10]. Methodically, all approaches use DNA se-
quencing coverages as input and rely on calling coverage
outliers after data normalization. Most of the current
algorithm requires sequencing of paired tumor and nor-
mal (germline) DNA samples [11] or utilize a normal
DNA references for normalization [10, 12, 13]. Outlier
detection relies on simple thresholding [7, 9, 14] or more
sophisticated methods of p-value estimation [8, 10] or
bootstrap based estimation of confidence intervals [15].
Ioncopy is a method for calling of CNAs from targeted
NGS data validated before [8], which can be run in two
modes either using only the cohort of interest as input (and
outlier detection by internal statistics) or making use of an
additional reference cohort (e.g. of normal tissue or blood
samples). The extended version presented here includes a
GUI for easy data upload and straightforward CNA analysis.
Implementation
Ioncopy is an R Shiny app that can be operated without
knowledge of the R programming language [16]. Input file
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format, analysis parameters and the formats of the output
files are described in the user manual (Additional file 1).
Amplicon coverages of the cohort of interest (and option-
ally additionally of a reference cohort) are used as input.
Coverage data are uploaded as one or several tab-separated
files. Data procession and CNA calling are performed as fol-
lows: 1. Sample normalization: Each sample is scaled with
the median of its amplicon coverages. 2. Amplicon
normalization: If reference coverages are available, each
amplicon is scaled by its median coverage in the reference
data. If no reference coverages are available, each amplicon is
scaled by its median coverage in the target data. Multiplica-
tion by two (corresponding to two alleles) is performed to
obtain estimates of copy numbers (CNs). 3. Significance as-
sessment for CNAs in each amplicon and each sample: First,
a normal distribution centered around CN=2 with variance
estimated from the median average deviation (mad) is fitted
to the distribution of CNs for each amplicon. Then, a p-value
is calculated for each amplicon and each sample assessing
the degree of being an outlier to normal distribution. 4. In
the mode “gene-wise”, the p-values of all amplicons interro-
gating a gene are summarized to a single p-value using Fish-
er’s method [17] and CNs are summarized by taking the
amplicon average. 5. Either, no multiple testing corrections,
multiple testing corrections with respect to samples, mul-
tiple testing corrections with respect to genes or multiple
testing corrections with respect to samples and genes are
done. Then, p-values are corrected to control either
family-wise error rate (FWER) or false discovery rate
(FDR) using the Bonferroni or the Benjamini-Hochberg
method respectively. 6. CNAs (gains and losses) are called
when passing the significance threshold (corrected p < 0.
05).
The intra-gene inconsistency (IGI) is a quality measure
for a sample s that is calculated from its amplicon cover-
ages CN(a, s) by
IGI sð Þ ¼
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:
Therein, G denotes the set of all genes, n(g) the number
and A(g) the set of amplicons interrogating the gene g. CN(g,
s) is the CN estimate for gene g calculated as average of
CN(a, s) over the amplicons a interrogating the gene g.
Higher IGI corresponds higher intra-gene variance of
CNs and is a technical issue related to inferior sample quality
in the most cases. The IGI for each sample is included in the
sample-centered output file of CNAs (CNAs samples: list).
Hierarchical clustering in the heatmap display is performed
using Manhattan distance and the average linkage method.
Results and discussion
As use case, we analyze 184 breast carcinoma sequenced
on an Ion Torrent PGM using a 154-amplicon-panel
and published before [8]. After loading of the ioncopy
package and starting of the app by runIoncopy(), data
upload and analysis can be performed GUI-based and
without knowledge of the R language (Fig. 1). First, the
Fig. 1 Screenshot of the Ioncopy GUI. The left panel functions to upload the matrix of sequencing coverages (amplicons × samples) and to start
the analysis. In the middle panel, the user chooses gene-wise or amplicon-wise analysis and a method to correct CNA p-values for multiple test-
ing. The appearance of the overview heatmap can be modified using the lower part of the middle panel. The right panel functions as result area
and offers download of tables including calculated copy numbers, significances and CNA calls
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coverage matrix of the breast cancer cohort (Add-
itional file 2) is uploaded as target coverage file. Upload
of a reference coverage matrix is optional and left out
here. After hitting “Go!” Ioncopy estimates CNs and sig-
nificances of CNAs for each gene in each sample. In the
middle panel of the GUI, it can be chosen to perform
the analysis either amplicon-wise or gene-wise. Multiple
testing corrections and CNA calling can be performed in
a more or a less stringent ways. In the gene-wise mode,
the user can chose to call only CNAs that are supported
by two or more calls of amplicons or by 50% (or another
selectable percentage) of the amplicons located in the
gene under consideration.
Operating Ioncopy in the gene-wise analysis mode, 396 (4.
5%) gains and 80 losses (0.9%) are detected for FWER con-
trol at p= 0.05 taking into account multiple testing for both
genes and samples. Out of these, 351 (4.0%) gains and 59 (0.
7%) losses are supported by calls of at least two amplicons.
The analysis mode of FWER control can be relaxed to FDR
control at 5%, which leads to detection of 856 (9.7%) gains
and 295 (3.3%) losses. Also, it is possible to run Ioncopy
without multiple testing corrections, which is recommend-
able only for usage as search test together with validation of
CNA candidates by an independent confirmatory test.
Called CNAs can be downloaded as matrix genes ×
samples, as gene-focused list or as sample-focused list.
The latter includes IGI as a sample quality measure that
is calculated from the CNs as described in the Imple-
mentation section. High IGI corresponding to inconsist-
ency of CNs within genes and inferior coverage data
quality, which is often detected in samples with low
DNA quality (data not shown).
Heatmaps are generated to display the estimated CNs or
the detected CNAs (Fig. 2). In the breast cancer data,
ERBB2, GRB7, STARD3 and MED1, all located in the
chromosomal region 17q12 and typically co-amplified in
HER2+ breast cancer, cluster tightly together. Several options
are available to influence the appearance of the heatmaps.
For example, sample clustering can be spared to preserve
the natural order of the input data what can be helpful
for technical quality control and exclusion of batch effects.
A limitation of NGS based CNA detection is tumor
purity, as detection sensitivity decreases significantly
when the tumor cell content falls below 50% [8]. For low
tumor content samples, spatial-dissolved assays such as
FISH should be preferred for CNA detection instead of
bulk tissue based detection methods.
Conclusions
Ioncopy is a freely available and easy-to-use method for
calling CNAs from targeted NGS data.
Availability and requirements
Project name: Ioncopy.
Project home page: https://cran.r-project.org/
package=ioncopy
Operating system: Platform independent.
Programming language: R Shiny.
License: GNU GPL 3.
Restrictions to use by non-academics: none.
Additional files
Additional file 1: Ioncopy user manual. Comprehensive description of
the input file format, of the analysis parameters and of the format of the
output files. (PDF 1690 kb)
Additional file 2: Breast cancer example data set. Coverage matrix of
152 amplicons (48 genes) in 184 breast cancer samples. (XLS 196 kb)
Fig. 2 Heatmaps of CN levels (a) and CNA calls (b). In both kinds of heatmaps samples and/or genes can be either left in the order of the input data
or be clustered. Sparing sample clustering can be helpful for technical quality control and exclusion of batch effects
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